Puma Biotechnology | PBYI - Pre Tax Profit


Puma Biotechnology reported $20.61M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 343.6M 46.34M Mar/2026
MacroGenics USD -14.93M 31.75M Dec/2025
Moderna USD -799M 612M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Takeda JPY -52.48B 186.34B Mar/2026
TG Therapeutics USD 20.36M 24.73M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026